Element's VITARI System Targets $100 Genome, Shaking Up the Sequencing Landscape

SAN DIEGO, CA – February 19, 2026 – Element Biosciences today threw down a new gauntlet in the fiercely competitive genomics market, announcing VITARI, a high-throughput benchtop sequencing system capable of delivering a high-quality whole genome for $100. The announcement signals a significant move to democratize powerful DNA sequencing, bringing technology once confined to large, specialized centers into the reach of everyday research labs.

With VITARI, the San Diego-based company expands its portfolio, which already includes the AVITI and AVITI24 systems, reinforcing its strategy of providing "right-sized" sequencing solutions across the research spectrum. The new system aims to eliminate the long-standing trade-off between quality, simplicity, and scale, empowering scientists to design more ambitious studies.

“VITARI is about removing limits from scientific ambition,” said Molly He, CEO and co-founder of Element Biosciences, in the company's official release. “By lowering the barriers to high-throughput sequencing for labs of all sizes, we’re improving workflows and giving researchers the freedom to design studies around biology—not the constraints of their tools.”

The $100 Genome Becomes a Benchtop Reality

The quest for the $100 genome has been a defining goal for the genomics industry for over a decade, representing a critical threshold for making population-scale studies and routine clinical genomics economically viable. While other companies, such as Ultima Genomics, have previously announced reaching this price point, Element's VITARI is notable for packaging this power within a compact benchtop instrument.

Historically, achieving such low costs required massive, factory-scale sequencers that demanded constant, high-volume sample batching to operate efficiently. This model often created logistical bottlenecks for smaller labs or projects with more moderate sample numbers. VITARI directly addresses this pain point. The system is engineered to deliver up to 10 billion reads, or 3 terabytes (TB) of data, per run, with data quality metrics promising over 90% of bases at Q30 or higher—a key benchmark for accuracy. This level of performance is comparable to, and in some cases exceeds, established platforms.

This combination of affordability and accessibility has profound implications. For researchers in fields like rare disease diagnostics, the ability to perform whole-genome sequencing (WGS) as a more routine procedure could dramatically shorten the diagnostic odyssey for countless families. In population health, the $100 price point makes it feasible to sequence entire cohorts, unlocking unprecedented insights into the genetic underpinnings of complex diseases like cancer, diabetes, and heart disease.

A New Challenger in a High-Stakes Market

The launch of VITARI is a clear strategic play to capture market share from the industry's dominant force, Illumina, which has long held an estimated 80-90% of the short-read sequencing market. Element is positioning VITARI as a powerful and flexible alternative to established platforms.

According to company specifications, VITARI offers approximately three times the throughput of an Illumina NextSeq 2000 while maintaining a similar physical footprint. While it has about half the raw output of a production-scale NovaSeq 6000, its key advantage lies in its operational flexibility. VITARI features two independent flow cells, each with six individually addressable lanes. This innovative design allows labs to run multiple, smaller projects simultaneously without waiting to batch samples, minimizing reagent waste and accelerating turnaround times from sample to answer.

This modularity directly counters the economic model of larger sequencers that penalize underutilized runs. Element's strategy appears focused on superior data quality and a more transparent, predictable cost structure. The company has previously committed to not raising reagent prices for its AVITI system over the instrument's lifetime, a policy that resonates with labs struggling with fluctuating operational budgets. Furthermore, VITARI’s use of ambient-temperature shipping for reagent cartridges simplifies logistics and reduces the hidden costs and environmental impact associated with maintaining a cold chain.

Beyond DNA: A Vision for a Multiomic Future

While the $100 genome is the headline-grabbing feature, VITARI is architected as more than just a DNA sequencer. It represents a platform for Element's broader vision of integrated, multiomic analysis, which seeks to provide a more holistic understanding of biology by simultaneously measuring multiple data types from a single sample.

The system's roadmap includes future integration of Element’s Teton™ and direct in-sample multiomic capabilities. Teton CytoProfiling, already available on the AVITI24 system, enables the simultaneous analysis of DNA, RNA, proteins, and phosphoproteins, all while preserving cellular morphology. This “5D” approach provides a deeply layered view of cellular states and signaling pathways, which is particularly crucial for complex fields like oncology and immunology.

Even more ambitious is the planned integration of Direct In Situ Sequencing (DISS), a technology for which Element has filed patents. Expected to become available in 2026, DISS will allow for spatial sequencing directly within tissue samples. This would be a monumental leap for spatial biology, enabling researchers to link genetic variant expression directly to a cell’s location and architectural context within the tissue, a capability that is currently fragmented across multiple complex workflows.

By building a system that excels at today's genomic applications while being primed for the next wave of multiomic and spatial technologies, Element is positioning VITARI not just as a tool for the present, but as a long-term investment for labs at the forefront of biological discovery. With a price tag of $689,000 and shipping slated to begin in the second half of 2026, the company reports that pre-orders are already open and early customer interest is strong, suggesting the scientific community is eager to see if VITARI can truly deliver on its transformative promise.